Clinical Trial: Treatment Development of Triheptanoin (G1D)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial

Brief Summary: To determine the maximum tolerated dose (MTD), as a percentage of calories consumed, of triheptanoin (C7 oil; C7) in a pediatric and adult patient population genetically diagnosed with glucose transporter type 1 deficiency disorder (G1D).

Detailed Summary:

The trial will use an open-label, standard 3+3 phase i design for determining the MTD of orally-administered C7 in G1D.

Triheptanoin: a triglyceride oil containing three odd-carbon chain-length fatty acids (i.e., a triglyceride of 7-carbon heptanoic acid). Triheptanoin will be taken 4 times per day (approximately every 6 hours) by mouth. it is dosed 4 times per day, divided evenly, and the total C7 daily dose will re-place 40% or 45% (depending on group) of the daily caloric intake from fat in the usual diet, based on current protocol guidelines. The oil should be taken approximately one hour before meals, and will be mixed with fat-free, sugar-free yogurt or pudding for administration.

Up to thirty-six subjects will be enrolled in a 10-day maximum tolerable dose trial of C7. initiation of C7 dosing will be conducted in the Children's Medical Center Dallas ambulatory Care Pavilion neurology Clinic. Sub-jects will be provided with C7 oil to take over the 7 days of administration.

Subjects will not be required to stop other medications. Subjects will be di-rected to maintain their usual medications, including rescue seizure medications, as necessary for the course of the study. Subjects may have any clinical medical records transferred back to their referring physician at completion of the study.


Sponsor: University of Texas Southwestern Medical Center

Current Primary Outcome: Maximum tolerated dose trial [ Time Frame: medication taken daily for 7 days. ]

To determine the MTD as a percentage of calories consumed in pediatric and adult patient population.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Texas Southwestern Medical Center

Dates:
Date Received: January 31, 2017
Date Started: March 29, 2017
Date Completion: March 29, 2025
Last Updated: May 18, 2017
Last Verified: May 2017